The latest annual report from the trade body of New Zealand’s pharmaceutical industry highlights some of the challenges facing the sector.
Medicines New Zealand says, compared with other countries, patients in New Zealand have to wait longer for innovative, cost-effective medicines.
The document highlights the fact that new medicines in New Zealand are typically on a waiting list for over a decade before a decision on reimbursement is reached. For higher priority drugs, the wait time is almost seven years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze